Celgene Co. (NASDAQ:CELG) Shares Sold by Bourne Lent Asset Management Inc.

Bourne Lent Asset Management Inc. cut its position in shares of Celgene Co. (NASDAQ:CELG) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 415,615 shares of the biopharmaceutical company’s stock after selling 7,050 shares during the quarter. Celgene comprises about 19.8% of Bourne Lent Asset Management Inc.’s holdings, making the stock its largest position. Bourne Lent Asset Management Inc. owned 0.06% of Celgene worth $41,271,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. First PREMIER Bank bought a new position in Celgene during the third quarter worth $26,000. Liberty Wealth Management LLC increased its stake in shares of Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 200 shares in the last quarter. Massey Quick Simon & CO. LLC purchased a new position in shares of Celgene in the second quarter worth about $33,000. Lenox Wealth Advisors LLC purchased a new position in shares of Celgene in the third quarter worth about $37,000. Finally, Capital Investment Advisory Services LLC increased its stake in shares of Celgene by 69.3% in the third quarter. Capital Investment Advisory Services LLC now owns 408 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 167 shares in the last quarter. Institutional investors own 72.49% of the company’s stock.

CELG opened at $104.52 on Friday. The business’s 50-day moving average is $99.70 and its two-hundred day moving average is $95.78. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $107.41. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32. The firm has a market capitalization of $74.41 billion, a PE ratio of 13.73, a price-to-earnings-growth ratio of 0.53 and a beta of 1.42.

Celgene (NASDAQ:CELG) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.22 billion. During the same quarter in the previous year, the firm earned $2.16 earnings per share. The firm’s quarterly revenue was up 15.4% compared to the same quarter last year. As a group, sell-side analysts expect that Celgene Co. will post 9.96 EPS for the current year.

In related news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the sale, the insider now owns 13,493 shares of the company’s stock, valued at $1,325,957.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.39% of the company’s stock.

Several brokerages have issued reports on CELG. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a research report on Tuesday, July 23rd. Mizuho reaffirmed a “hold” rating and issued a $100.00 target price on shares of Celgene in a research note on Sunday, October 20th. Cowen reaffirmed a “hold” rating and issued a $102.00 target price on shares of Celgene in a research note on Tuesday, July 30th. ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Finally, BidaskClub raised shares of Celgene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, seventeen have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $94.60.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.